Free Newsletter
MedImmune CEO talks about AZ buyout
MedImmune's chief executive talked publicly for the first time about AstraZeneca's April takeover of his company--and his assessment of his new corporate parent is, not surprisingly, positive. David M. Mott did get to keep his job, and MedImmune is adding to its staff of 3,000, rather than slicing away at jobs as the rest of AstraZeneca is. Plus, Mott expects R&D spending to ramp up significantly, to $1 billion by 2010 from $400 million last year. Big Pharma is fun, he essentially said. It probably helps that he made a cool $145 million off the deal himself.
- check out the report
Related Articles:
AstraZeneca snares MedImmune in $15.6B buyout. Report
MedImmune investor urges company to seek bidders. Report
MedImmune goes on the auction block. Report
AstraZeneca lays out road map for recovery. Report
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
SHARE
WITH: